ETE. M. Tarasova

E. M. Tarasova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


E. M. Tarasova has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Ю. Ю. Трунин

    ФГАУ «НМИЦ нейрохирургии им. ак. Н.Н. Бурденко» Минздрава России

    3 shared publications
  • Alexander Karachunsky

    Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

    2 shared publications
  • E. F. Valiakhmetova

    N.N. Burdenko National Medical Research Center of neurosurgery Ministry of Healthcare of Russian Federation

    2 shared publications
  • Galina. A. Novichkova

    Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia

    2 shared publications
  • L. A. Lasareva

    N.N. Burdenko National Medical Research Center of neurosurgery Ministry of Healthcare of Russian Federation

    2 shared publications
  • L. V. Shiskina

    N.N. Burdenko National Medical Research Center of neurosurgery Ministry of Healthcare of Russian Federation

    2 shared publications

Latest Publications

  • Melanotic neuroectodermal tumor of infancy. Clinical case of large fontanel tumor and literature review

    by R.B. Mai, D.A. Reshchikov, I.G. Vasiliev, V.E. Popov, E.M. Tarasova, M.A. Senchenko

    Melanotic neuroectodermal tumor of infancy (MNTI) is a neonatal tumor with progressive growth and high recurrence rate. Aggressive growth and localization of tumor often lead to significant cosmetic defects of cranial and facial bones. The authors report MNTI in a 6-month-old boy with lesion of the large fontanel. Total resection was followed by recurrence after 3 weeks. Repeated resection with subsequent radiotherapy was performed. The follow-up period was 6 months after repeated resection. There was no tumor growth throughout this period. Considering this case and world experience, we can conclude that treatment strategy for MNTI is still unclear.

  • Open Access

    PEDIATRIC OPTIC PATHWAY GLIOMA: DIENCEPHALIC SYNDROME

    by A. F. Valiakhmetova, N. A. Mazerkina, L. I. Papusha, O. I. Bydanov, E. M. Tarasova, O. A. Medvedeva, N. K. Serova, L. A. Lazareva, L. V. Shishkina, Yu. Yu. Trunin, et al.

    Diencephalic cachexia (DC ) is a metabolic disorder characterized by a decrease in body weight. DC usually occurs in the presence of glioma brain tumors extended into the optic pathway. These tumors are very aggressive and have poor prognosis.Objective: to analyze the clinical course of optic pathway gliomas (OPG s) in patients with and without DC .Material and Methods. The study included 264 patients aged 0 to 18 years with an initial diagnosis of OPG s registered in the N.N. Burdenko National Medical Research Center of neurosurgery from 01/01/2003 to 12/31/2015. Patients were divided into two groups: without DC (204 people) and with DC (60 children). Results: neurofibromatosis type I (NFI) was much more common in children without DC , and pilomyxoid histology was much more prevalent in children with DC . Five-year overall survival (OS ) and event-free survival EFS were significantly lower in children with DC than in children without DC (82 ± 5 % and 96 ± 1 %, respectively versus 37 ± 7 % and 62 ± 3 %, respectively). It was found that in the DC group, the OS and EFS rates were significantly lower in girls, in children without NFI, in children without histological verification and in children with pilocytic astrocytomas. It was also found that in the DC group, OS rates were significantly lower in children under 1 year, and EFS rates were significantly lower in children aged more than 12 months. The number of patients without events were significantly higher in the group without DC (p=0.001). The number of deaths in the postoperative period was significantly higher in children with DC (pConclusion. OPG s in patients with DC have a more aggressive clinical course, which requires more careful treatment and observation.


  • Open Access

    Optic pathway gliomas associated with neurofibromatosis type I in children

    by E. F. Valiakhmetova, N. A. Mazerkina, O. A. Medvedeva, Y. Y. Trunin, E. M. Tarasova, L. A. Lasareva, L. V. Shiskina, N. K. Serova, S. K. Gorelyshev, Ю. Ю. Трунин

    Neurofibromatosis type I (NFI) is one of the most common brain tumor predisposition syndromes. Children with NFI are prone to develop a low grade gliomas, which can be localized in various areas of the brain, however, most of them occur in the structures of the optic pathway: optic nerves, chiasm, tracts and optic radiations – that is, are optic pathway gliomas (OPG). This retrospective study included children with newly diagnosied low grade glioma of the optic pathway at the age from 0 to 18 years with NFI, who underwent medical examination and / or treatment at the Burdenko Neurosurgery Institute from January 1, 2003 till December 31,2015. Atotal from 264 patients 42 (16%) had clinical manifestations of NFI. The ratio of boys and girls was 1:1. The median age was 4.25 years (range 4.5 months – 17 years). Visual disturbances were the most frequent clinical manifestation of the tumor. Surgical resection was performed in 18 patients. The remaining 24 patients OPG were diagnosed based on clinical and radiological findings: 9 patients were in observation group, 11 patients chemotherapy was carried out, three were given radiation therapy, and spontaneous regression of the tumor was recorded in 1 patient. Progression of the disease was observed in 14 patients in our cohort. The overall survival rate in patients with NFI was 98 ± 2% at 5 years. Event free survival rate was 68 ± 7% at 5 years.The study was approved by the Independent Ethics Committee of N.N. Burdenko National Medical Research Center of neurosurgery Ministry of healthcare ofRussian Federation.

  • Open Access

    Optic pathway gliomas associated with neurofibromatosis type I in children

    by E. F. Valiakhmetova, N. A. Mazerkina, O. A. Medvedeva, Y. Y. Trunin, E. M. Tarasova, L. A. Lasareva, L. V. Shiskina, N. K. Serova, S. K. Gorelyshev, Ю. Ю. Трунин

    Neurofibromatosis type I (NFI) is one of the most common brain tumor predisposition syndromes. Children with NFI are prone to develop a low grade gliomas, which can be localized in various areas of the brain, however, most of them occur in the structures of the optic pathway: optic nerves, chiasm, tracts and optic radiations – that is, are optic pathway gliomas (OPG). This retrospective study included children with newly diagnosied low grade glioma of the optic pathway at the age from 0 to 18 years with NFI, who underwent medical examination and / or treatment at the Burdenko Neurosurgery Institute from January 1, 2003 till December 31,2015. Atotal from 264 patients 42 (16%) had clinical manifestations of NFI. The ratio of boys and girls was 1:1. The median age was 4.25 years (range 4.5 months – 17 years). Visual disturbances were the most frequent clinical manifestation of the tumor. Surgical resection was performed in 18 patients. The remaining 24 patients OPG were diagnosed based on clinical and radiological findings: 9 patients were in observation group, 11 patients chemotherapy was carried out, three were given radiation therapy, and spontaneous regression of the tumor was recorded in 1 patient. Progression of the disease was observed in 14 patients in our cohort. The overall survival rate in patients with NFI was 98 ± 2% at 5 years. Event free survival rate was 68 ± 7% at 5 years.The study was approved by the Independent Ethics Committee of N.N. Burdenko National Medical Research Center of neurosurgery Ministry of healthcare ofRussian Federation.


  • Open Access

    Prognostic value of molecular, genetic and clinical characteristics of SHH group medulloblastoma

    by L. I. Papusha, A. E. Druy, L. A. Yasko, Z. S. Supik, L. Z. Zemtsova, A. P. Ektova, D. M. Konovalov, K. A. Voronin, A. A. Merishavyan, I. D. Borodina, et al.

    SHH group of medulloblastoma is a heterogeneous tumor cohort. The neoplasms differ by biological characteristics as well as clinical features and prognosis of the disease. Purpose of the study is the analysis of clinical, molecular and genetic features for prognosis defining in patients with SHH group medulloblastoma. 28 patients with SHH group medulloblastomas were included in the study. The MB molecular group verification was performed in parallel by Nanostring gene expression profiling and immunohistochemical assessment of tumor samples. The detection of TP53 gene mutations was carried out with Sanger sequencing. The prognostic impact of the clinical, molecular and genetic factors of the disease was analyzed by calculating 5-years event-free survival (EFS). The median of follow up time achieved 38.9 months. All patients harboring the TP53 mutation (n = 3) had dismal outcome (two patients died from the progression of the disease, one patient has secondary tumor). Children from older age group ( 3 years) had more adverse events comparing to younger children ( 3 years): EFS 49.2 ± 31.3% vs. 78.8 ± 13.9%. The relapse of the disease occurred in 7 patients (25%). Notably, that in younger children the second line treatment was effective. The presence of TP53 mutations as well as age above 3 years are associated with poor prognosis in SHH group medulloblastomas. The novel molecular and genetics markers are needed for precise prognosis defining.